122 related articles for article (PubMed ID: 9794434)
1. Novel C-terminally truncated isoforms of the CXC chemokine beta-thromboglobulin and their impact on neutrophil functions.
Ehlert JE; Gerdes J; Flad HD; Brandt E
J Immunol; 1998 Nov; 161(9):4975-82. PubMed ID: 9794434
[TBL] [Abstract][Full Text] [Related]
2. The amino-terminal residues in the crystal structure of connective tissue activating peptide-III (des10) block the ELR chemotactic sequence.
Malkowski MG; Lazar JB; Johnson PH; Edwards BF
J Mol Biol; 1997 Feb; 266(2):367-80. PubMed ID: 9047370
[TBL] [Abstract][Full Text] [Related]
3. Connective tissue-activating peptide III desensitizes chemokine receptors on neutrophils. Requirement for proteolytic formation of the neutrophil-activating peptide 2.
Härter L; Petersen F; Flad HD; Brandt E
J Immunol; 1994 Dec; 153(12):5698-708. PubMed ID: 7989767
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of neutrophil functions by the ELR(+) CXC chemokine platelet basic protein.
Ehlert JE; Ludwig A; Grimm TA; Lindner B; Flad HD; Brandt E
Blood; 2000 Nov; 96(9):2965-72. PubMed ID: 11049972
[TBL] [Abstract][Full Text] [Related]
5. Thrombin-activated human platelets release two NAP-2 variants that stimulate polymorphonuclear leukocytes.
Piccardoni P; Evangelista V; Piccoli A; de Gaetano G; Walz A; Cerletti C
Thromb Haemost; 1996 Nov; 76(5):780-5. PubMed ID: 8950790
[TBL] [Abstract][Full Text] [Related]
6. Relationship between neutrophil-binding affinity and suitability for infection imaging: comparison of (99m)Tc-labeled NAP-2 (CXCL-7) and 3 C-terminally truncated isoforms.
Rennen HJ; Frielink C; Brandt E; Zaat SA; Boerman OC; Oyen WJ; Corstens FH
J Nucl Med; 2004 Jul; 45(7):1217-23. PubMed ID: 15235069
[TBL] [Abstract][Full Text] [Related]
7. Formation of neutrophil-activating peptide 2 from platelet-derived connective-tissue-activating peptide III by different tissue proteinases.
Car BD; Baggiolini M; Walz A
Biochem J; 1991 May; 275 ( Pt 3)(Pt 3):581-4. PubMed ID: 2039437
[TBL] [Abstract][Full Text] [Related]
8. NH2- and COOH-terminal truncations of murine granulocyte chemotactic protein-2 augment the in vitro and in vivo neutrophil chemotactic potency.
Wuyts A; D'Haese A; Cremers V; Menten P; Lenaerts JP; De Loof A; Heremans H; Proost P; Van Damme J
J Immunol; 1999 Dec; 163(11):6155-63. PubMed ID: 10570306
[TBL] [Abstract][Full Text] [Related]
9. Platelet-derived chemokines CXC chemokine ligand (CXCL)7, connective tissue-activating peptide III, and CXCL4 differentially affect and cross-regulate neutrophil adhesion and transendothelial migration.
Schenk BI; Petersen F; Flad HD; Brandt E
J Immunol; 2002 Sep; 169(5):2602-10. PubMed ID: 12193731
[TBL] [Abstract][Full Text] [Related]
10. Limited and defined truncation at the C terminus enhances receptor binding and degranulation activity of the neutrophil-activating peptide 2 (NAP-2). Comparison of native and recombinant NAP-2 variants.
Ehlert JE; Petersen F; Kubbutat MH; Gerdes J; Flad HD; Brandt E
J Biol Chem; 1995 Mar; 270(11):6338-44. PubMed ID: 7890771
[TBL] [Abstract][Full Text] [Related]
11. The neutrophil-activating proteins interleukin 8 and beta-thromboglobulin: in vitro and in vivo comparison of NH2-terminally processed forms.
Van Damme J; Rampart M; Conings R; Decock B; Van Osselaer N; Willems J; Billiau A
Eur J Immunol; 1990 Sep; 20(9):2113-8. PubMed ID: 2145175
[TBL] [Abstract][Full Text] [Related]
12. Neutrophil-activating peptides NAP-2 and IL-8 bind to the same sites on neutrophils but interact in different ways. Discrepancies in binding affinities, receptor densities, and biologic effects.
Petersen F; Flad HD; Brandt E
J Immunol; 1994 Mar; 152(5):2467-78. PubMed ID: 8133058
[TBL] [Abstract][Full Text] [Related]
13. Increased microvascular permeability in vivo in response to intradermal injection of neutrophil-activating protein (NAP-2) in rabbit skin.
Van Osselaer N; Van Damme J; Rampart M; Herman AG
Am J Pathol; 1991 Jan; 138(1):23-7. PubMed ID: 1824807
[TBL] [Abstract][Full Text] [Related]
14. A novel molecular variant of the neutrophil-activating peptide NAP-2 with enhanced biological activity is truncated at the C-terminus: identification by antibodies with defined epitope specificity.
Brandt E; Petersen F; Flad HD
Mol Immunol; 1993 Aug; 30(11):979-91. PubMed ID: 7688853
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 8, neutrophil-activating peptide-2 and GRO-alpha bind to and elicit cell activation via specific and different amino acid residues of CXCR2.
Katancik JA; Sharma A; de Nardin E
Cytokine; 2000 Oct; 12(10):1480-8. PubMed ID: 11023662
[TBL] [Abstract][Full Text] [Related]
16. Nuclear magnetic resonance solution structure of truncated human GRObeta [5-73] and its structural comparison with CXC chemokine family members GROalpha and IL-8.
Qian YQ; Johanson KO; McDevitt P
J Mol Biol; 1999 Dec; 294(5):1065-72. PubMed ID: 10600366
[TBL] [Abstract][Full Text] [Related]
17. Production of chemokines CTAPIII and NAP/2 by digestion of recombinant ubiquitin-CTAPIII with yeast ubiquitin C-terminal hydrolase and human immunodeficiency virus protease.
Mildner AM; Paddock DJ; LeCureux LW; Leone JW; Anderson DC; Tomasselli AG; Heinrikson RL
Protein Expr Purif; 1999 Jul; 16(2):347-54. PubMed ID: 10419831
[TBL] [Abstract][Full Text] [Related]
18. The CXC chemokine NAP-2 mediates differential heterologous desensitization of neutrophil effector functions elicited by platelet-activating factor.
Schwartzkopff F; Brandt E; Petersen F; Flad HD; Bock L; Ludwig A
J Interferon Cytokine Res; 2002 Feb; 22(2):257-67. PubMed ID: 11911809
[TBL] [Abstract][Full Text] [Related]
19. The beta-thromboglobulins and platelet factor 4: blood platelet-derived CXC chemokines with divergent roles in early neutrophil regulation.
Brandt E; Petersen F; Ludwig A; Ehlert JE; Bock L; Flad HD
J Leukoc Biol; 2000 Apr; 67(4):471-8. PubMed ID: 10770278
[TBL] [Abstract][Full Text] [Related]
20. Chemotactic activity and receptor binding of neutrophil attractant/activation protein-1 (NAP-1) and structurally related host defense cytokines: interaction of NAP-2 with the NAP-1 receptor.
Leonard EJ; Yoshimura T; Rot A; Noer K; Walz A; Baggiolini M; Walz DA; Goetzl EJ; Castor CW
J Leukoc Biol; 1991 Mar; 49(3):258-65. PubMed ID: 1997632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
